SCHEMBL3205573

SCHEMBL3205573

CC(C)(C)c1ccc(OCCn2c(=N)n(Cc3ccccc3)c3ccccc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.54
LMNA P02545 9/20 0.54
SMN1; SMN2 Q16637 7/20 0.54
NPSR1 Q6W5P4 1/20 0.53
MAPT P10636 2/20 0.53
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
MITF O75030 2/20 0.52
ALDH1A1 P00352 2/20 0.52
TSHR P16473 3/20 0.51
GPR55 Q9Y2T6 1/20 0.50
SLC5A2 P31639 2/20 0.49
HTT P42858 2/20 0.49
HCRTR2 O43614 1/20 0.48
ALOX15 P16050 1/20 0.48
HSD17B10 Q99714 1/20 0.48
KDM4E B2RXH2 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3194875 0.95 TP53 (0.56) TP53LMNASMN1; SMN2NPSR1MAPT
SCHEMBL3205551 0.87 LMNA (0.67) TP53LMNASMN1; SMN2NPSR1KMT2A
SCHEMBL3194997 0.86 LMNA (0.69) TP53LMNASMN1; SMN2NPSR1MAPT
SCHEMBL3194234 0.81 LMNA (0.65) TP53LMNASMN1; SMN2NPSR1MAPT
SCHEMBL3188073 0.80 SLC5A2 (0.64) TP53LMNASMN1; SMN2NPSR1MAPT
SCHEMBL3205881 0.80 TP53 (0.74) TP53LMNASMN1; SMN2NPSR1MAPT
SCHEMBL3207909 0.79 TP53 (0.68) TP53LMNASMN1; SMN2NPSR1MAPT
SCHEMBL2493076 0.78 TP53 (0.73) TP53LMNASMN1; SMN2NPSR1MAPT
SCHEMBL2493856 0.78 MAPT (0.64) TP53LMNASMN1; SMN2NPSR1MAPT
SCHEMBL3206483 0.77 LMNA (0.63) TP53LMNASMN1; SMN2NPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2010-02-11 US disclosed
EP-2041096-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL- CONDUCTANCE CALCIUM-ACTIVATED POTATIUM CHANNELS NeuroSearch AS (DK) 2009-04-01 EP disclosed
WO-2008003752-A1 2 -AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL - CONDUCTANCE CALCIUM -ACT IVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 TP53 4533/4885LMNA 2392/4885SMN1; SMN2 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.